Benefit of olaparib in the treatment of ovarian cancer – clinical practice

Abstract

For many years, ovarian cancer was considered as a sad disease, which is usually diagnosed in locally advanced disease and often relapses. The treatment options were surgery and chemotherapy.

The change occurred with the use of poly (ADP-ribose) polymerase (PARP) inhibitors, which improve patient survival and prolong the time until disease progression. Olaparib was the first available PARP inhibitor.